These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10629403)

  • 1. What else can 'Heparin' do?
    Lindahl U
    Haemostasis; 1999 Dec; 29 Suppl S1():38-47. PubMed ID: 10629403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Heparin'--from anticoagulant drug into the new biology.
    Lindahl U
    Glycoconj J; 2000; 17(7-9):597-605. PubMed ID: 11421351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of biologically active heparan sulfate and heparin using an enzyme-based approach.
    Peterson S; Frick A; Liu J
    Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin-binding domains in vascular biology.
    Muñoz EM; Linhardt RJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1549-57. PubMed ID: 15231514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparan sulfate and heparin interactions with proteins.
    Meneghetti MC; Hughes AJ; Rudd TR; Nader HB; Powell AK; Yates EA; Lima MA
    J R Soc Interface; 2015 Sep; 12(110):0589. PubMed ID: 26289657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low anticoagulant heparin retains anti-HIV type 1 activity in vitro.
    Coombe DR; Harrop HA; Watton J; Mulloy B; Barrowcliffe TW; Rider CC
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1393-6. PubMed ID: 8573397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
    Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
    Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
    Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
    Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
    Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant heparan sulfate: structural specificity and biosynthesis.
    Liu J; Pedersen LC
    Appl Microbiol Biotechnol; 2007 Feb; 74(2):263-72. PubMed ID: 17131147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decorin endocytosis: structural features of heparin and heparan sulphate oligosaccharides interfering with receptor binding and endocytosis.
    Hausser H; Kresse H
    Biochem J; 1999 Dec; 344 Pt 3(Pt 3):827-35. PubMed ID: 10585870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfamate proton solvent exchange in heparin oligosaccharides: evidence for a persistent hydrogen bond in the antithrombin-binding pentasaccharide Arixtra.
    Langeslay DJ; Young RP; Beni S; Beecher CN; Mueller LJ; Larive CK
    Glycobiology; 2012 Sep; 22(9):1173-82. PubMed ID: 22593556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent innovations in the structural analysis of heparin.
    Yates EA; Rudd TR
    Int J Cardiol; 2016 Jun; 212 Suppl 1():S5-9. PubMed ID: 27264867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the structure of antithrombin-binding heparan sulfate generated by heparan sulfate 3-O-sulfotransferase 5.
    Chen J; Liu J
    Biochim Biophys Acta; 2005 Sep; 1725(2):190-200. PubMed ID: 16099108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid formation by the model protein muscle acylphosphatase is accelerated by heparin and heparan sulphate through a scaffolding-based mechanism.
    Motamedi-Shad N; Monsellier E; Chiti F
    J Biochem; 2009 Dec; 146(6):805-14. PubMed ID: 19675100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assays and reference materials for current and future applications of heparins.
    Mulloy B; Hogwood J; Gray E
    Biologicals; 2010 Jul; 38(4):459-66. PubMed ID: 20338781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding.
    Herold BC; Gerber SI; Polonsky T; Belval BJ; Shaklee PN; Holme K
    Virology; 1995 Feb; 206(2):1108-16. PubMed ID: 7856085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin affin regulatory peptide modulates the endogenous anticoagulant activity of heparin and heparan sulphate mimetics.
    Mejdoubi-Charef N; Courty J; Sineriz F; Papy-Garcia D; Charef S
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):296-302. PubMed ID: 22672269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.